New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 22, 2013
10:00 EDTBCEI, TTS, JIVE, CR, USAC, ROLL, VRX, FANG, VSTM, OFG, PDCE, XOM, CVX, BRCMOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Broadcom (BRCM) initiated with an Overweight at Piper Jaffray... Chevron (CVX) initiated with a Buy at Canaccord... Exxon Mobil (XOM) initiated with a Hold at Canaccord... Oriental Financial (OFG) initiated with a Buy at Jefferies... PDC Energy (PDCE) initiated with an Outperform at Iberia... Verastem (VSTM) initiated with a Buy at Guggenheim... Valeant (VRX) initiated with a Buy at Aegis... Diamondback Energy (FANG) initiated with a Buy at Brean Capital... USA Compression (USAC) initiated with an Outperform at Raymond James... RBC Bearings (ROLL) reinstated with a Buy at BofA/Merrill... Crane (CR) initiated with a Buy at Ascendiant Capital... Tile Shop (TTS) initiated with an Outperform at Wedbush... Jive Software (JIVE) initiated with an Outperform at Northland Securities... Bonanza Creek (BCEI) initiated with a Buy at Brean Capital.
News For BRCM;CVX;XOM;PDCE;OFG;VSTM;FANG;VRX;ROLL;USAC;CR;JIVE;TTS;BCEI From The Last 14 Days
Check below for free stories on BRCM;CVX;XOM;PDCE;OFG;VSTM;FANG;VRX;ROLL;USAC;CR;JIVE;TTS;BCEI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 14, 2014
08:02 EDTVRXValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
06:58 EDTFANGDiamondback Energy shares undervalued, says Wells Fargo
Subscribe for More Information
July 11, 2014
16:48 EDTVRXAllergan comments on Pershing Square’s definitive proxy solicitation
Allergan (AGN) provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management in connection with Pershing Square’s request to call a Special Meeting of Stockholders. At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals' (VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer. Under the current Board’s leadership, which includes individuals with significantly more industry experience than Pershing Square’s recommended nominees, Allergan continues to execute on its plan to drive near- and long-term organic growth, enhance its growth prospects and continue generating significant value for all of Allergan’s stockholders. We believe Pershing Square’s attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price that substantially undervalues the company and creates significant risks and uncertainties for Allergan stockholders. Valeant has repeatedly failed to address the serious concerns raised by Allergan and important members of the investment community about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues. Allergan has a track record of consistently acting in the best interests of its stockholders and the Board remains confident in the company’s ability to create significantly more value than Valeant’s proposal.
July 10, 2014
17:08 EDTCVXChevron reports Q2-May U.S. upstram production 665 MBOED vs. 659 MBOED in 2Q13
Subscribe for More Information
17:05 EDTCVXChevron sees Q2 earnings higher than Q1
Subscribe for More Information
16:09 EDTVSTMVerastem says lead cancer stem cell inhibitor VS-6063 continues to show promise
Verastem hosted its annual Research and Development Day, at which it reports it said, "We continue to see promising clinical signals from the VS-6063 program. An additional partial response has been reported since our interim report at ASCO on the combination of VS-6063 and weekly paclitaxel in twenty-two patients with ovarian cancer. To date, best clinical response of at least stable disease has been observed in 14 of the 22 patients. This comprises two complete responses, three partial responses and nine patients with stable disease, including four patients whose disease has been stable for 6 months or longer. Eight patients continue on study drug. Based on this encouraging activity, we are planning a controlled Phase 2 study in patients with platinum resistant ovarian cancer.” The company also noted that it has made "significant progress in the past 12 months and have continued to further scientific understanding with all of our product candidates." Encouraged by these initial signs of clinical activity, the company reported it is adding additional studies to further test its hypothesis that the targeting of cancer stem cells may enable a more durable clinical response.
13:46 EDTXOMExxon feels singled-out in regards to fracking, WSJ says
Exxon Mobil is up against a criminal lawsuit over a wastewater spill in Pennsylvania and is saying that the state's attorney general has incorrectly singled it out in an effort to stop fracking, according to The Wall Street Journal, citing comments from Attorney General Kathleen Kane. Lawyers are saying that Exxon unit, XTO Energy, is criminally responsible for a large leak of water that had been used in hydraulic fracturing, or fracking, in north-central Pennsylvania four years ago. Reference Link
11:00 EDTTTSHigh option volume stocks
High option volume stocks: CBS MEMP EWT CBSO DRWI TRW TTS EXK MEOH AG
10:18 EDTTTSHome Depot, Lowe's estimates cut after warnings from floor, farm retailers
Weak results from Tractor Supply (TSCO) and Lumber Liquidators (LL) do not bode well for Home Depot (HD) and Lowe's (LOW) near-term outlook, Deutsche Bank warned in a note to investors earlier today. WHAT'S NEW: After hardwood floors retailer Lumber Liquidators and farm products retailer Tractor Supply pre-announced weaker than expected Q2 results, Deutsche Bank analyst Mike Baker reduced his estimates for Home Depot and Lowe's. The comparative sales of Home Depot and Lowe's have historically had a positive correlation with those of Tractor Supply and Lumber Liquidators, explained Baker. Lumber Liquidators, like Home Depot and Lowe's, is exposed to housing markets, the analyst stated. Meanwhile, like Tractor Supply, Home Depot and Lowe's are exposed to the outdoor/weather sensitive sector, according to Baker. However, there are differences in the companies' business models, and comparative sales at Home Depot and Lowe's are probably trending better than at Tractor Supply and Lumber Liquidators, Baker believes. He lowered his second quarter comparative sales growth forecast for Lowe's to 4% from 4.5%, and for Home Depot to 4.5% from 5%. Baker's Q2 EPS estimates for both home improvement companies are now 1c below consensus levels. He kept a Buy rating on Lowe's and Hold ratings on Home Depot and Tractor Supply. PRICE ACTION: In early trading, Home Depot fell 2% to $79.07, Lowe's declined 1.8% to $47.02, Tractor Supply tumbled 5% to $58.23, and Lumber Liquidators plunged 22% to $54.70. Shares of Tile Shop (TTS), which is also exposed to housing markets, fell 11% to $11.55 in early trading.
09:31 EDTVRXNestle acquires rights to aesthetic dermatology products in the U.S. and Canada
Subscribe for More Information
09:31 EDTVRXValeant completes filler, toxin asset sale to Galderma
Subscribe for More Information
09:15 EDTTTSOn The Fly: Pre-market Movers
HIGHER: Zumiez (ZUMZ), up 5.7% after raising Q2 outlook... DragonWave (DRWI), up 5% after reporting better than expected Q1 results... International Game (IGT), up 3.6% after Italian press report says the company will soon get a $4B offer from GTECH... United Continental (UAL), up 2.9% after reporting June traffic. LOWER: Lumber Liquidators (LL), down 23% after downgraded at Jefferies and Credit Suisse following the company's reduced full-year outlook. Tile Shop (TTS), which also serves flooring customers, down 5.5% following Lumber Liqudators' profit warning... Family Dollar (FDO), down 1.9% after reporting Q3 earnings that missed expectations... Tractor Supply (TSCO), down 5.9% after reporting Q2 preliminary results, saying it now sees FY14 results at low end of guidance range... Liquidity Services (LQDT), down 8% after revising Q3 guidance after its sales of selected rolling stock and other assets under its Surplus Contract with the U.S. Defense Logistics Agency have ceased at the request of DLA... Potbelly (PBPB), down 18% after lowering its Q2 and FY14 outlook... Memorial Production Partners (MEMP), down 7.4% after filing to sell 8.6M shares of common units for partners... Kosmos (KOS), down 3.3% after filing to sell 17M shares of common stock.
07:03 EDTTTSTile Shop estimates lowered on Lumber Liquidators results at Credit Suisse
Credit Suisse lowered Tile Shop (TTS) estimates following weak Lumber Liquidators (LL) results. The analyst said Tile Shop's comps have a high correlation to Lumber Liquidators and said its not immune to weaker macro factors. Shares remain Outperform rated with a $16 price target, down from $18.
July 9, 2014
18:50 EDTTTSOn The Fly: After Hours Movers
Subscribe for More Information
18:31 EDTVRXShareholders urge Allergan to make large acquisition, FT reports
Subscribe for More Information
18:21 EDTVRXAllergan CEO seeks sizeable acquisitions, WSJ reports
Subscribe for More Information
18:09 EDTTTSLumber Liquidators plummets after cutting full-year outlook
Shares of hardwood flooring and accessories retailer Lumber Liquidators (LL) are sinking in after-hours trading after the company cut its fiscal 2014 outlook. It also forecast second quarter results far below analysts' consensus estimates. WHAT'S NEW: After the bell, Lumber Liquidators forecast Q2 earnings per share of 59c-61c, far short of the consensus estimate of 90c. Q2 sales came in at $263.1M, also well below estimates of $303.21M. Comparable store sales decreased 7.1% for the quarter, and the company expects gross margin in Q2 to contract year over year. WHAT'S NOTABLE: Due to the weak Q2 performance, the company cut its FY14 EPS view to $2.65-$3.00 from $3.25-$3.60, versus consensus of $3.34. It also lowered its FY14 revenue outlook to $1.05B-$1.1B from $1.15B-$1.2B, versus consensus of $1.16B. It forecast comparable store net sales in the low single digits, either positive or negative, compared to its previous view of an increase ranging from mid to high single digits. It sees opening a total of 33 to 37 new store locations in the expanded showroom format, down from the previous view of 35 to 40. CEO Lynch said, "A number of the factors weighing on our second quarter results are likely to continue in the second half of 2014. While we believe the third quarter may be weaker than we originally anticipated, we have a strong sense of urgency and we expect to regain traction to deliver operating margin expansion in the second half and in coming years." PRICE ACTION: In evening trading, Lumber Liquidators fell $13.52, or 19.2%, to $56.90 on heavy trading volume. OTHERS TO WATCH: Other companies in the flooring space include Tile Shop (TTS), down 5%, Home Depot (HD), down 1%, and Lowe's (LOW), down 1.8%.
10:02 EDTBRCMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:19 EDTVRXAllergan plans broad restructuring plan, Bloomberg says
Allergan (AGN), the pharmaceutical maker that is being chased by Valeant (VRX) and Bill Ackman’s hedge fund, will shelve unpromising pipeline medicines and revamp management incentives, according to Bloomberg, citing two people with knowledge of the matter. The sources said that the restructuring plan, which is set to be explained during Allergan's upcoming earnings announcement, will also detail companywide cost reductions including some legacy expenses. Reference Link
05:33 EDTBRCMBroadcom upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use